---
title: "ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 | IBRX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288311834.md"
description: "ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 | IBRX Stock News"
datetime: "2026-06-01T09:55:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288311834.md)
  - [en](https://longbridge.com/en/news/288311834.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288311834.md)
---

# ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 | IBRX Stock News

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 | IBRX Stock News

### Related Stocks

- [IBRX.US](https://longbridge.com/en/quote/IBRX.US.md)

## Related News & Research

- [ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation | IBRX Stock News](https://longbridge.com/en/news/287354508.md)
- [ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline](https://longbridge.com/en/news/272866307.md)
- [Are Daiichi Sankyo Company’s (TSE:4568) ASCO 2026 ADC Data Deepening Its Oncology Moat?](https://longbridge.com/en/news/288948995.md)
- [<![CDATA[What’s Trending in Oncology? A Discussion Following ASCO 2026 with Anne Marie Robertson from EVERSANA]]>](https://longbridge.com/en/news/288700390.md)
- [ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026 | TLX Stock News](https://longbridge.com/en/news/288327814.md)